The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production

European Neuropsychopharmacology

Volumn 18, Issue 1, 2008, Pages 24-33

  Danovich, Lena ^a   Veenman, Leo ^a   Leschiner, Svetlana ^a   Lahav, Michal ^a   Shuster, Vered ^a   Weizman, Abraham ^b,c   Gavish, Moshe ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antipsychotics; Clozapine; Neurosteroids; Peripheral type benzodiazepine receptor (PBR); Translocator protein (TSPO)

Indexed keywords

BENZODIAZEPINE RECEPTOR; CLOZAPINE; CORTICOSTERONE; NEUROLEPTIC AGENT; PROGESTERONE; RISPERIDONE; STEROID; SULPIRIDE; TESTOSTERONE; THIORIDAZINE; TRANSLOCATOR PROTEIN 18; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG PROTEIN BINDING; GLIA CELL; GLIOMA CELL; HIPPOCAMPUS; HORMONE SYNTHESIS; HYPOTHALAMUS; LEYDIG CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEROIDOGENESIS; TESTOSTERONE BLOOD LEVEL;

ADRENAL GLANDS; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CELL LINE; CLOZAPINE; CORTICOSTERONE; HUMANS; ISOQUINOLINES; MALE; MICE; MITOCHONDRIA; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA; RISPERIDONE; STEROIDS; SULPIRIDE; TESTIS; TESTOSTERONE; THIORIDAZINE;

EID: 36749099096     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.04.005     Document Type: Article

References (57)

1. 3H]PK 11195 to cerebral cortex and peripheral tissues of various species: species differences and heterogeneity in peripheral benzodiazepine binding sites. J. Neurochem. 49 (1987) 1407-1414
2. Barbaccia M.L., Affricano D., Purdy R.H., Maciocco E., Spiga F., and Biggio G. Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology 25 (2001) 489-497
3. Barkey R.J., Weiss-Messer E., Hacham H., Herscovich S., Ber R., and Amit T. Prolactin and testicular Leydig cell function: characterization of prolactin receptors in the murine MA-10 testicular Leydig cell line. Proc. Soc. Exp. Biol. Med. 206 (1994) 243-248
4. Bauminger S., Kohen F., Lindner H.R., and Weinstein A. Antiserum to 5alpha-dihydrotestosterone: production, characterization and use in radioimmunoassay. Steroids 24 (1974) 477-488
5. Belelli D., and Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci. 6 (2005) 565-575
6. Bitran D., Foley M., Audette D., Leslie N., and Frye C.A. Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat. Psychopharmacology (Berl) 15 1 (2000) 64-71
7. Boujrad N., Gaillard J.L., Garnier M., and Papadopoulos V. Acute action of choriogonadotropin on Leydig tumor cells: induction of a higher affinity benzodiazepine-binding site related to steroid biosynthesis. Endocrinology 135 (1994) 1576-1583
8. Boujrad N., Vidic B., Gazouli M., Culty M., and Papadopoulos V. The peroxisome proliferator perfluorodecanoic acid inhibits the peripheral-type benzodiazepine receptor (PBR) expression and hormone-stimulated mitochondrial cholesterol transport and steroid formation in Leydig cells. Endocrinology 141 (2000) 3137-3148
9. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
10. Breier A., Buchanan R.W., Kirkpatrick B., et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 151 (1994) 20-26
11. Carmel I., Fares F.A., Leschiner S., Scherubl H., Weisinger G., and Gavish M. Peripheral-type benzodiazepine receptors in the regulation of proliferation of MCF-7 human breast carcinoma cell line. Biochem. Pharmacol. 58 (1999) 273-278
12. Delavoie F., Li H., Hardwick M., et al. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 42 (2003) 4506-4519
13. Farnbach-Pralong D., Bradbury R., Copolov D., and Dean B. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. Eur. J. Pharmacol. 349 (1998) R7-R8
14. Frankenburg F.R. Choices in antipsychotic therapy in schizophrenia. Harv. Rev. Psychiatry 6 (1999) 241-249
15. Gavish M., Weizman A., Karp L., Tyano S., and Tanne Z. Decreased peripheral benzodiazepine binding sites in platelets of neuroleptic-treated schizophrenics. Eur. J. Pharmacol. 121 (1986) 275-279
16. Gavish M., Bachman I., Shoukrun R., et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 51 (1999) 629-650
17. Golani I., Weizman A., Leschiner S., et al. Hormonal regulation of peripheral benzodiazepine receptor binding properties is mediated by subunit interaction. Biochemistry 40 (2001) 10213-10222
18. Green A.I., Tohen M., Patel J.K., et al. Clozapine in the treatment of refractory psychotic mania. Am. J. Psychiatry 157 (2000) 982-986
19. Guidotti A., Auta J., Davis J.M., et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 180 (2005) 191-205
20. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 174 (2004) 151-162
21. Hippius H. A historical perspective of clozapine. J. Clin. Psychiatry 60 Suppl 12 (1999) 22-23
22. Kane J.M., Honigfeld G., Singer J., and Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol. Bull. 24 (1988) 62-67
23. Kapur S., and Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158 (2001) 360-369
24. Kapur S., Zipursky R.B., and Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156 (1999) 286-293
25. Kelly-Hershkovitz E., Weizman R., Spanier I., et al. Effects of peripheral-type benzodiazepine receptor antisense knockout on MA-10 Leydig cell proliferation and steroidogenesis. J. Biol. Chem. 273 (1998) 5478-5483
26. Korpi E.R., Wong G., and Luddens H. Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine. Naunyn-Schmiedebergs Arch. Pharmacol. 352 (1995) 365-373
27. Kurumaji A., Wakai T., and Toru M. Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J. Neural Transm. 104 (1997) 1361-1370
28. Lacapere J.J., and Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 68 (2003) 569-585
29. Levin E., Premkumar A., Veenman L., et al. The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line. Biochemistry 44 (2005) 9924-9935
30. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
31. Marx C.E., VanDoren M.J., Duncan G.E., Lieberman J.A., and Morrow A.L. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28 (2003) 1-13
32. McEnery M.W., Snowman A.M., Trifiletti R.R., and Snyder S.H. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3170-3174
33. Mellon S.H., and Griffin L.D. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol. Metab. 13 (2002) 35-43
34. Meltzer H.Y. Treatment of suicidality in schizophrenia. Ann. N.Y. Acad. Sci. 932 (2001) 44-58 (discussion 58-60)
35. Moore N.A., Rees G., Sanger G., and Tye N.C. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav. Pharmacol. 5 (1994) 196-202
36. Mortimer A.M. Antipsychotic treatment in schizophrenia: atypical options and NICE guidance. Eur. Psychiatr. 18 (2003) 209-219
37. Papadopoulos V., Mukhin A.G., Costa E., and Krueger K.E. The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. J. Biol. Chem. 265 (1990) 3772-3779
38. Papadopoulos V., Boujrad N., Ikonomovic M.D., Ferrara P., and Vidic B. Topography of the Leydig cell mitochondrial peripheral-type benzodiazepine receptor. Mol. Cell. Endocrinol. 104 (1994) R5-R9
39. Papadopoulos V., Baraldi M., Guilarte T.R., et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27 (2006) 402-409
40. Patchev V.K., Shoaib M., Holsboer F., and Almeida O.F. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 62 (1994) 265-271
41. Patchev V.K., Hassan A.H., Holsboer D.F., and Almeida O.F. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 15 (1996) 533-540
42. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 345 (1995) 557-562
43. Ranjan R., and Meltzer H.Y. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol. Psychiatry 40] (1996) 253-258
44. Rupprecht R., and Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22 (1999) 410-416
45. Sharma V. Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disord. 5 Suppl 2 (2003) 48-52
46. Stanniland C., and Taylor D. Tolerability of atypical antipsychotics. Drug Safety 22 (2000) 195-214
47. Suppes T., Webb A., Paul B., Carmody T., Kraemer H., and Rush A.J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am. J. Psychiatry 156 (1999) 1164-1169
48. Ugale R.R., Hirani K., Morelli M., and Chopde C.T. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology 29 (2004) 1597-1609
49. Veenman L., and Gavish M. Peripheral-type benzodiazepine receptors: their implication in brain disease. Drug Dev. Res. 50 (2000) 355-370
50. Veenman L., and Gavish M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol. Ther. 110 (2006) 503-524
51. Veenman L., Leschiner S., Spanier I., Weisinger G., Weizman A., and Gavish M. PK 11195 attenuates kainic acid-induced seizures and alterations in peripheral-type benzodiazepine receptor (PBR) protein components in the rat brain. J. Neurochem. 80 (2002) 917-927
52. Veenman L., Levin E., Weisinger G., et al. Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines. Biochem. Pharmacol. 68 (2004) 689-698
53. Wagstaff A., and Perry C. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs 17 (2003) 273-280 (discussion 281-273)
54. Weisinger G., Kelly-Hershkovitz E., Veenman L., Spanier I., Leschiner S., and Gavish M. Peripheral benzodiazepine receptor antisense knockout increases tumorigenicity of MA-10 Leydig cells in vivo and in vitro. Biochemistry 43 (2004) 12315-12321
55. Weizman R., Tanne Z., Karp L., Tyano S., and Gavish M. Peripheral-type benzodiazepine-binding sites in platelets of schizophrenics with and without tardive dyskinesia. Life Sci. 39 (1986) 549-555
56. Weizman R., Burgin R., and Gavish M. Modulatory effect of antidepressants on peripheral-type benzodiazepine receptors. Eur. J. Pharmacol. 250 (1993) 289-294
57. Worrel J.A., Marken P.A., Beckman S.E., and Ruehter V.L. Atypical antipsychotic agents: a critical review. Am. J. Health-Syst. Pharm. 57 (2000) 238-255